AstraZeneca Announced Earlier, Tagrisso Plus Chemotherapy Granted Priority Review In The US For Patients With EGFR-Mutated Advanced Lung Cancer
Portfolio Pulse from Charles Gross
AstraZeneca's supplemental New Drug Application (sNDA) for Tagrisso in combination with chemotherapy has been granted Priority Review by the FDA for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer. The FDA's decision is expected in the first quarter of 2024.
October 16, 2023 | 8:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Tagrisso has been granted Priority Review by the FDA, potentially offering a significant improvement over available treatments for advanced lung cancer.
The FDA's Priority Review status for AstraZeneca's Tagrisso indicates a recognition of the drug's potential significance in treating advanced lung cancer. This could lead to increased investor confidence in AstraZeneca, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100